ライフサイエンスコーパス: IV

1 50%), ereA (for erythromycin; 27.41%), aac-3-IV (for gentamicin; 25.38%), and the two genes cmlA (24.

2 or stop the resident's manual activity (8); IV) take over (9).

3 nous tPA (tissue-type plasminogen activator; IV tPA) in acute ischemic stroke patients with prior isc

4 Studies have shown that collagen alpha3 (IV) chains, a major constituent component of the basemen

5 T, Mayo staging was I/II in 8, III in 3, and IV in 10.

6 utions: I, 17.4%; II, 22.9%; III, 33.7%; and IV, 48.7% (P = 0.014).

7 successfully implemented in half-Huesler and IV-VI compounds.

8 o of which were found to contain Sudan I and IV residues.

9 ve nuclear CTNNB1status in CRC stage III and IV (35% of all CRC) was not different from stage I and I

10 pants had periodontitis, with stages III and IV found in 26.1% and 52.9%, respectively.

11 patients with periodontitis (Stages III and IV) after non-surgical periodontal treatment.

12 ) patients with advanced (ie, stages III and IV) clear cell RCC treated by nephrectomy; after exclusi

13 ee most prevalent LASV lineages (II, III and IV).

14 er patients with periodontitis Stage III and IV, Grade C respond well to the non-surgical periodontal

15 and II, n = 186) and B (Koos grades III and IV, n = 72).

16 mean %LINE-1 demethylation between oral and IV were <=1%.

17 Gs including visualization capabilities and (IV) prioritizing of GO-terms.

18 ApoA-IV levels were decreased in serum from allergic patients

19 nd meta-ROI SUVRs were not elevated in Braak IV or primary age-related tauopathy.

20 in the lung, a first event, and followed by IV lipopolysaccharide, a second event, resulted in ARDS

21 cytosolic CA I, CA II, and membrane-bound CA IV.

22 ability when a chemical oxidant was used (Ce(IV) , 7400 turnovers, TOF 0.88 s(-1) ).

23 gene SlHAK20 encoding a member of the clade IV HAK/KUP/KT transporters.

24 s, tooth level analysis (Class III and Class IV groups) found less residual REC and increased KT in t

25 nosed systemic lupus erythematosus and class IV lupus nephritis confirmed with biopsy and treated wit

26 rk Heart Association (NYHA) functional class IV HF was an exclusion criterion.

27 Here, ~39 kDa class IV chitinase (HrCHI4) was purified from seabuckthorn see

28 0.1 viruses induced from an existing cluster IV A(H3N2)v vaccine and several seasonal inactivated inf

29 In humans, cluster IV A(H3N2)v vaccine induced antibodies cross-reactive to

30 uses in cluster 2010.1 than those in cluster IV in adults.

31 s revealed that 2 is a low-spin (S = 1/2) Co(IV) species with the unpaired electron located on the co

32 nating resting state of the catalyst as a Co(IV) species CoO(2).

33 to form an open core species X-Co(III)-O-Co(IV)-O (1-X).

34 e spin density heavily delocalized in the Co(IV)-O unit.

35 knot, dysregulation of nephrin and collagen IV, and ultrastructural changes in the trilaminar filtra

36 structural ECM genes (fibronectin, collagen IV, collagen VI, myocilin), matricellular genes (connect

37 ion of the sulfilimine crosslink in collagen IV in basement membranes.

38 -like branches in ECs and increased collagen IV and laminin expression.

39 alternative falsification test that compares IV balance or bias with the balance or bias that would h

40 cell lines depleted of the catalytic complex IV subunit COX1 or COX2.

41 esence of COX1 independently of holo-complex IV formation.

42 a component of cytochrome c oxidase (complex IV).

43 Although complex-IV and citrate synthase activities were similar in VOE p

44 c and Statistical Manual of Mental Disorders IV criteria) diagnosed after the age of 55 (LOD group) a

45 of SCN5A in the S4 voltage sensor of domain IV and stably integrated the library into HEK293T cells.

46 significant difference between the high-dose IV iron group compared with the lose-dose group in event

47 The high-dose and low-dose IV iron groups exhibited identical infection rates.

48 alysis for ESKD to a high-dose or a low-dose IV iron regimen, with a primary composite outcome of all

49 nzyme (ACE) and dipeptidyl peptidase IV (DPP-IV) inhibitory activities, with inhibition of ACE being

50 ition of ACE being stronger than that of DPP-IV.

51 IIAEKTKIPAVF, IDALNENK, and VLVLDTDYK), DPP-IV-inhibitory peptides (LKALPMH, LKPTPEGDLEIL, LKGYGGVSL

52 three times a week) nonmedical use, and DSM-IV cannabis use disorder were estimated for groups with

53 Statistical Manual of Mental Disorders (DSM-IV).

54 ial beta-lactam agent administered as either IV push or IV piggyback.

55 r in a nonperioperative setting using either IV or intramuscular ketamine were included for analysis.

56 he pristine structures of the Fe(III) and Fe(IV) =O redox states of a B-type DyP.

57 nteract directly with the oxido ligand in Fe(IV)-oxido complexes, which weakens the Fe=O bond and has

58 hat is drastically different from nonheme Fe(IV)-oxo synthetic model complexes; (3) The OAT step most

59 knowledge gap, we introduced a series of Fe(IV)-oxido complexes that have the same S = 2 spin ground

60 An important structural aspect of [Fe(IV)poat(O)](-) is the inclusion of an auxiliary site cap

61 ate (high-valent diamond-core bis-mu-oxo-[Fe(IV)](2) unit) is involved in the reaction mechanism.

62 High-valent Fe(IV)=O intermediates with a terminal metal-oxo moiety are

63 I skin type group and 68% in the Fitzpatrick IV-VI skin type group (P = 0.79).

64 of emulsifier, hindered the polymorphic form IV-to-V transition.

65 d the role of germinal cell kinase four (GCK-IV) kinases in cell death and additionally revealed thei

66 Finally, we also found that GCK-IV kinase inhibition also prevented the attrition of RGC

67 d with genome editing, we validated that GCK-IV kinase knockout improves neuronal survival, comparabl

68 rget Na(V)s, compared with HwTx-IV and gHwTx-IV.

69 he activity of the peptide can improve gHwTx-IV's potency and selectivity for Na(V)1.7.

70 ovel analogues was weaker than that of gHwTx-IV, but stronger than that of HwTx-IV, suggesting a poss

71 [R26A]gHwTx-IV consistently displayed the most improved potency and

72 FTP grade IV is an independent risk factor for velum-CCC, controll

73 ealed that CCC was associated with FTP grade IV.

74 s seen in 27 patients; no patients had grade IV bone marrow toxicity.

75 Glioblastoma (GBM), or grade IV astrocytoma, is a malignant brain cancer that contain

76 atients with World Health Organization grade IV glioblastomas 40 mm or less from the IHM region, loss

77 7.8%, and depended on injury severity (grade IV (free rupture) 20.9%).

78 index (BMI), and tonsil size (TS), the grade IV individuals had a 4.4-fold higher risk of having CCC

79 e a novel prognostic biomarker for WHO grade IV glioma patient outcomes.

80 HalphaT was associated with grade IV venom anaphylaxis (relative risk = 2.0; P < .05) and

81 IL5 and IL13 were highly expressed in group IV; however, groups IV and V differed in age (34 vs 14 y

82 ighly expressed in group IV; however, groups IV and V differed in age (34 vs 14 years [P < .05]).

83 The H5 LPAIVs of the HA-III and HA-IV subgroups appeared in 2015 and 2017 in unusually high

84 into three subgroups (HA-II, HA-III, and HA-IV).

85 S, habitat III), and tidal flat (TF, habitat IV) across a salinity gradient.

86 nctional impact of alterations in huwentoxin-IV sequence, we produced a library of 373 point mutants

87 of gHwTx-IV, but stronger than that of HwTx-IV, suggesting a possible relationship between in vitro

88 ngside off-target Na(V)s, compared with HwTx-IV and gHwTx-IV.

89 patients with earlier Braak stages (Braak I-IV) did not show elevated tracer uptake in these regions

90 elin) and scored for cortical lesion types I-IV (mixed grey matter/white matter, intracortical, subpi

91 All hiatal hernia types (I-IV) were collected.

92 ration of Gynecology and Obstetrics stage IC-IV ovarian cancer and an Eastern Cooperative Oncology Gr

93 tive for Chronic Obstructive Lung Disease II-IV) who were carefully characterized (including airway m

94 rom ex vivo glioma tissue (n = 16, grades II-IV) to quantify metabolite concentrations.

95 thetic nucleus (SPN), dorsal horn laminae II-IV, and dorsal commissural nucleus (SDCom).

96 or Chronic Obstructive Lung Disease stage II-IV COPD and persistent symptoms and/or serum C-reactive

97 ogical subtype, or any FIGO (1988) stage IIB-IV epithelial cancer of the ovary, fallopian tube, or pr

98 ondrial protein components of complexes III, IV, and V.

99 xcitatory neurons in cortical layers II-III, IV, and V, as well as the dentate gyrus.

100 manganese ions results in high-valent Mn(III,IV)-oxide nanoparticles of the birnessite type bound to

101 (EMD) in the treatment of multiple Class III-IV Miller periodontal recession (REC) defects on mandibu

102 width 36 months after treatment of Class III-IV REC on mandibular anterior teeth.

103 None had grade III-IV acute or chronic graft-versus-host disease.

104 Grade III-IV adverse events were equivalent between arms (62.2%).

105 d deeper within the dorsal horn (laminae III-IV) are important for both types of injuries.

106 ck squamous cell carcinoma (HNSCC; stage III-IV according to the Union for International Cancer Contr

107 DAC samples (102 stage I-II and 97 stage III-IV); 50.7% were from female individuals.

108 ork Heart Association functional classes III/IV (5.2%/year); 67% have survived, including 31 with hea

109 ngs indicate that locomotor muscle group III/IV afferent feedback in patients with HFrEF leads to inc

110 FrEF is excessive locomotor muscle group III/IV afferent feedback; however, this has never been inves

111 the influence of locomotor muscle group III/IV afferent inhibition via lumbar intrathecal fentanyl o

112 Group III/IV muscle afferents transduce nociceptive signals and mo

113 te paw withdrawal movements, and laminae III/IV INs modulate dynamic corrective reflexes.

114 was lower and peak stretch higher in POP III/IV compared to non-POP and POP I/II in the main in vivo

115 nts with histologically confirmed stage IIIB-IV NSCLC who were treated with immune checkpoint blockad

116 te 153, a largely community-based phase IIIb/IV study, to evaluate the impact of 1-year fixed-duratio

117 nt is complete with a total of 19 Stage IIIC-IV OC patients in first remission after conventional the

118 5,6]-membered palladacycle intermediate, Int-IV.

119 Intravenous (IV) succinate-induced PMN sequestration in the lung, a f

120 ummarize the available oral and intravenous (IV) iron formulations for the treatment of IDA in CKD.

121 ave raised concerns that giving intravenous (IV) iron to patients, such as individuals receiving main

122 eted a full course of inpatient intravenous (IV) antibiotics, (2) received a partial course of IV ant

123 an concerns about the safety of intravenous (IV) iron products and erythropoiesis-stimulating agents

124 come a predictive tool to study intravenous (IV) therapeutic proteins.

125 the nitrogen radical intermediate to the Ir(IV) species in the catalytic cycle.

126 es (n=9) demonstrated typical n-shaped I(K1) IV relationship; however, following isoproterenol, max o

127 ized to 1 of 3 arginine doses: (1) 100 mg/kg IV 3 times/day (TID); (2) loading dose (200 mg/kg) then

128 ased expression of calcium/calmodulin kinase IV (CAMK4).

129 double-positive cells, including Hpse+ layer IV cells targeting parvalbumin+ interneurons, leading to

130 etinin with 54% in layer II/III, 8% in layer IV, and 13% in layer V.

131 d staining, predominantly in Cortical Layers IV and VI in 27 of the 32 cats used in the study, with f

132 ceived ROP screening examinations at a level IV neonatal intensive care unit over a 7-year period.

133 n, we defined a new severity category (level IV) with prolonged exposure to supplemental O2 (>=120 da

134 -NHEJ to be strictly dependent on DNA Ligase IV, XRCC4 and XLF, members of the canonical branch of NH

135 al prerequisite for ligation by XRCC4:Ligase IV (X4L4).

136 ell transfusion and discuss using first-line IV iron monotherapy to treat anemic patients with cancer

137 tor expressing the glycoprotein of a lineage IV strain of LASV.

138 thanide (Ln) ions, molecular complexes of Ln(IV) were known only for cerium and more recently terbium

139 of host factor PCBP2 that binds to stem-loop IV of the IRES.

140 Pt(IV) aryl complexes (Ar = p-FC(6)H(4)) LPt(IV)F(py)(Ar)X (X = CN, Cl, 4-OC(6)H(4)NO(2)) and LPt(IV)

141 (Ar)X (X = CN, Cl, 4-OC(6)H(4)NO(2)) and LPt(IV)F(2)(Ar)(HX) (X = NHAlk; Alk = n-Bu, PhCH(2), cyclo-C

142 When a difluoro complex LPt(IV)F(2)(Ar)(py) is treated with TMS-X (TMS = trimethylsi

143 the Ar-X coupling but without observable LPt(IV)F(py)(Ar)X intermediates.

144 thylation, and safety vs decitabine 20 mg/m2 IV in the first 2 cycles, with similar efficacy.

145 erall oxidation state of either Mn(III)(3)Mn(IV) or Mn(III)Mn(IV)(3) for the S(2) state.

146 and multifrequency EPR spectroscopy of a Mn(IV)(4)O(4) cuboidal complex as a spectroscopic model of

147 sults indicate the amounts of Mn(III) and Mn(IV) species in MnO(x) and CaMnO(3) depend on potential.

148 tate of either Mn(III)(3)Mn(IV) or Mn(III)Mn(IV)(3) for the S(2) state.

149 idation of the previously reported Mn(III)Mn(IV)(3)O(4) cuboidal complex to the Mn(IV)(4)O(4) complex

150 III)Mn(IV)(3)O(4) cuboidal complex to the Mn(IV)(4)O(4) complex described here.

151 Results show that this Mn(IV)(4)O(4) complex has an S = 3 ground state with isotro

152 All 18 eyes (9 patients) with MPS IV had normal angle structures, but 8 eyes (4 patients)

153 4 patients with MPS II, 9 patients with MPS IV, and 6 patients with MPS VI) and 20 normal control su

154 ly inhibited the tumor growth after multiple IV injection.

155 confirming the generality of the Ni(II) -> N(IV) protocol, either in the presence of bipyridine, or u

156 Thus, understanding the stability of NCU(IV) in the environment is of crucial importance.

157 Their impact on the stability of NCU(IV) is not well understood.

158 n of FeS drive this rapid reoxidation of NCU(IV).

159 ntribution of reactive oxygen species to NCU(IV) reoxidation.

160 ied the junctional receptor CNTNAP4/Neurexin-IV (Nrx-IV) and the membrane cytoskeletal effector Adduc

161 d for lipid distributions, making COOH-NHMe (IV) a potential next generation universal matrix.

162 ts demonstrate the superiority of COOH-NHMe (IV) in detecting more lipid and protein species compared

163 Further, COOH-NHMe (IV) showed a unique performance and was successfully app

164 junctional receptor CNTNAP4/Neurexin-IV (Nrx-IV) and the membrane cytoskeletal effector Adducin/Hu-li

165 charge, and (3) received a partial course of IV antibiotics and were prescribed oral antibiotics on A

166 ntibiotics, (2) received a partial course of IV antibiotics but were not prescribed any antibiotics o

167 ver, there are limited data on the safety of IV tPA in this population.

168 years or older with resected stage IIIB-C or IV melanoma and an Eastern Cooperative Oncology Group pe

169 ographic findings at discharge (grade III or IV aortic regurgitation, pulmonary hypertension) identif

170 better than they neutralized lineage III or IV GP expressing pseudoviruses.

171 s appropriate for patients with Stage III or IV periodontitis and can be recommended in dental practi

172 mellitus (DM) in patients with Stage III or IV periodontitis using the FINDRISC questionnaire.

173 65% New York Heart Association Class III or IV, nearly all on a loop diuretic, and 70% with a HF hos

174 New York Heart Association class II, III, or IV) and an ejection fraction of less than 45% to receive

175 ctam agent administered as either IV push or IV piggyback.

176 Oral/IV ratios of geometric LSM 5-day AUClast (80% confidence

177 (geometric least-squares mean [LSM]) of oral/IV 5-day area under curve from time 0 to last measurable

178 Alkyl-Pd(IV) complexes are frequently invoked in the proposed mec

179 e and isolable OCO pincer-supported alkyl-Pd(IV) complexes containing cyclopalladated alkylamine and

180 ich represent the first examples of alkyl-Pd(IV) complexes derived from the oxidation of cyclopallada

181 The aminoalkyl-Pd(IV) complexes reacted efficiently with O- and N-nucleoph

182 ization reactions, though few examples of Pd(IV) complexes containing cyclopalladated substrates have

183 I) intermediate to high-valent Pd(III) or Pd(IV) intermediates, which promotes the formation of C-O b

184 due to the instability of the high-valent Pd(IV) center.

185 ivated by the action of dipeptidyl peptidase IV (DPP-4) which limits their use as therapeutic agents.

186 erting enzyme (ACE) and dipeptidyl peptidase IV (DPP-IV) inhibitory activities, with inhibition of AC

187 e, we introduce conjugation between platinum(IV) prodrugs of cisplatin and perfluoroaryl peptide macr

188 Pol IV is expressed at increased levels in E. coli cells exp

189 vation can up-regulate and activate DinB/pol IV, the bacterial ortholog of Polkappa, to induce mutage

190 liana), DNA-dependent RNA polymerase IV (Pol IV) is required for the formation of transposable elemen

191 the Escherichia coli DNA polymerase IV (pol IV).

192 perhaps explaining the essential role of Pol IV in pollen development in Capsella.

193 f NRPD1, encoding the largest subunit of Pol IV, in the Brassicaceae species Capsella (Capsella rubel

194 Despite this proposed role of Pol IV, its loss of function in Arabidopsis does not cause a

195 nduced by antibiotics strongly stimulate pol IV activity.

196 s of the multidomain Y-family DNA polymerase IV (DPO4).

197 osed for the Escherichia coli DNA polymerase IV (pol IV).

198 psis thaliana), DNA-dependent RNA polymerase IV (Pol IV) is required for the formation of transposabl

199 The Proactive IV Iron Therapy in Haemodialysis Patients (PIVOTAL) tria

200 +19-enhancer and the leukemic prone promoter IV interaction for TAL1 activation in T-ALL.

201 -ALL cells, the leukemia-prone TAL1 promoter-IV specifically interacts with the +19 stem cell enhance

202 ive elimination from a series of isolated Pt(IV) aryl complexes (Ar = p-FC(6)H(4)) LPt(IV)F(py)(Ar)X

203 ive elimination reactions of all isolated Pt(IV) complexes follow first-order kinetics and were model

204 u may be due to cycling between Pu(V) and Pu(IV).

205 f Pu-UiO-66 demonstrates adept control of Pu(IV) coordination under hydrolysis-prone conditions, prov

206 ter migration than previous studies using Pu(IV) or Pu(III) sources.

207 Briefly, FVIII-deficient mice received IV emicizumab 24 hours before tail-clip bleeding was per

208 in crus I, paraflocculus, and vermal regions IV/V and VI - highlighting these regions as potential hu

209 The repeated IV administration of C-miR146a inhibited expression of N

210 rome (IBS), respectively, as defined by Rome IV criteria; and, 2) relationships between nausea and mu

211 oms of constipation not included in the Rome IV criteria, such as daily failure to defecate and an av

212 The survey included the Rome IV Diagnostic Questionnaire, Rome III irritable bowel sy

213 S(IV) is further oxidized to SO(4)(2-) in the presence of

214 hase laboratory experiments coupled to the S(IV)-autooxidation chemistry of isoprene, 3-methyl-2(5H)-

215 ly via the Wechsler Adult Intelligence Scale IV (IQ range, 40-160, standardized to a mean of 100 [SD,

216 Single-cell RNA sequencing showed that SNP-IV induced stem-like genes (Tcf7, Slamf6, Xcl1) whereas

217 Intravenous vaccination (SNP-IV) induced a higher proportion of TCF1(+)PD-1(+)CD8(+)

218 trated complete clinical response in a Stage IV MCC patient treated with PI3K inhibitor idelalisib.

219 c factors, although the guidelines for stage IV disease do not account for how these factors may infl

220 hy individuals, and was prognostic for stage IV patients.

221 Decreased OC/P RS was found in stage IV Appalachian white males within a subset of states.

222 Also, ADAR expression level in stage IV was higher than stage III.

223 stage II, 30% of stage III, and 32% of stage IV colorectal cancer cases.

224 nase inhibitors (TKI), the majority of stage IV melanoma patients eventually succumb to the disease.

225 patients with resected stage IIIB-C or stage IV melanoma, showed significant improvements in recurren

226 levated lactate dehydrogenase level or stage IV) or acute leukemia to compare the addition of six dos

227 ts were diagnosed at stages other than stage IV.

228 ts were diagnosed at stages other than stage IV; for 19 of the 20 studied symptoms (all except for ne

229 d 30-day mortality among patients with stage IV cancer.

230 le patients and 77 male patients) with stage IV CRC who underwent molecular profiling and pretreatmen

231 rospectively included 79 patients with stage IV lung carcinomas (n=24), renal carcinomas (n=11), or m

232 Patients with stage IV measurable disease were eligible to receive VI (vincr

233 Of 14 patients with stage IV measurable disease who received VI, 11 (79%) achieved

234 le patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or

235 on systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC) without driver alt

236 CTC-derived nucleases in subjects with stage IV PDAC in a phase I clinical trial.

237 II) study of different successional stages, (IV) use of environmentally relevant concentrations of bi

238 However, at oxidation state IV, complex 2(+) becomes seven coordinated with the two

239 n of Sudan I, Sudan II, Sudan III, and Sudan IV dyes.

240 a simple, readily-accessible alkyl sulfinyl (IV) chloride allows formation of a trigonal bipyramidal

241 Herein, we report a sulfur (IV) mediated cross-coupling amendable for the efficient

242 ncluding the Tc(I) [fac-Tc(CO)(3)](+) and Tc(IV) compounds.

243 de like hematite at pH 6.00 +/- 0.07, and Tc(IV) incorporation into magnetite via Fe(III) substitutio

244 quent inner-sphere complexation of Tc(IV)-Tc(IV) dimers onto a Fe oxide like hematite at pH 6.00 +/-

245 d subsequent inner-sphere complexation of Tc(IV)-Tc(IV) dimers onto a Fe oxide like hematite at pH 6.

246 sm involves the reduction from Tc(VII) to Tc(IV) and subsequent inner-sphere complexation of Tc(IV)-T

247 The IV push group was less likely to fail the goal of beta-l

248 The IV push strategy did not affect mortality, need for ICU

249 rsistent faradaic current peaks dominate the IV cycle of the junction (+/-2 V) in ACN vapor, enhancin

250 ovariate judgments about the validity of the IV design.

251 re classified as having an FTP grade of I to IV, and the velum, oropharynx, tongue base, epiglottis (

252 ent in outcomes of patients with stage II to IV DAWT compared with historical controls treated with r

253 nts aged at least 12 years with grades II to IV steroid-refractory aGVHD were eligible to receive rux

254 ork Heart Association functional class II to IV with a left ventricular (LV) ejection fraction <=40%

255 Type IV pili are flexible filaments on the surface of bacteri

256 The cag PAI encodes a type IV secretion system (T4SS) that mediates delivery of the

257 on, defining a monophyletic group among type IV pilins.

258 cular adenoma and carcinoma on Bethesda type IV lesions.

259 sk for follicular carcinoma in Bethesda type IV thyroid nodules but their absence does not allow to p

260 arttin variant associated with human BS type IV.

261 teristic of human Bartter syndrome (BS) type IV.

262 effects on erythroid physiology in CDA type IV.

263 ith the presence of a novel chromosomal type IV secretion system.

264 e cytoplasmic entrance of the F-encoded type IV secretion system (T4SS).

265 in the gonadal BM, where it facilitates type IV collagen removal during BM expansion and tissue growt

266 hatases; a set of 20 genes required for type IV pili function; and several conditionally essential ge

267 ubsequent pathology require the Dot/Icm Type IV Secretion System (T4SS) to deliver effector proteins

268 niche, C. burnetii requires the Dot/Icm type IV secretion system (T4SS) to translocate a cohort of ef

269 patients tend to have plateau iris; MPS type IV patients are vulnerable to open-angle glaucoma; MPS t

270 construct using the dynamic activity of type IV competence pili in V. cholerae as a model system.

271 ost usual, followed by the lower-outer (type IV).

272 h diversity microbiota, Community State Type IV-B, was the most prevalent in both HIV-negative (38% a

273 -di-GMP) and requires production of the type IV mannose-sensitive hemagglutinin (MSHA) pilus.

274 Caulobacter crescentus We identify the type IV pilin protein PilA as the primary signaling input tha

275 r tetracycline resistance [tet(O)], the Type IV secretion system, conjugative transfer and the Type V

276 ly situated, immature postmitotic type, Type IV cells.

277 ief that natural organic matter (OM) binds U(IV) and mediates its fate in the subsurface.

278 quiv of HNEt(3)BPh(3) yielded the cationic U(IV)/U(IV) nitride complex, [{((Me(3)Si)(2)N)(2)U(THF)}(2

279 th H(2) to produce an imide hydride U(III)/U(IV) complex, [{((Me(3)Si)(2)N)(2)U(THF)}(2)(mu-NH)(mu-H)

280 able to reduce soluble U(VI) to insoluble U(IV), providing a method for removal of U from contaminat

281 Treatment of the previously reported U(IV)/U(IV) nitride complex [Na(DME)(3)][((Me(3)Si)(2)N)(2)U(mu-

282 f HNEt(3)BPh(3) yielded the cationic U(IV)/U(IV) nitride complex, [{((Me(3)Si)(2)N)(2)U(THF)}(2)(mu-N

283 final speciation of U was nanoparticulate U(IV) uraninite, and this phase was evident at 2 days at p

284 Treatment of the previously reported U(IV)/U(IV) nitride complex [Na(DME)(3)][((Me(3)Si)(2)N)(2

285 pared upon photolysis with UV light of the U(IV) azide analogue.

286 ts, where it accumulates as tetravalent U [U(IV)], a form once considered largely immobile.

287 Further FLP reactivity between the uranium(IV)-amide, dihydrogen, and triphenylborane is suggested

288 Studies using IV iron have had somewhat greater success, showing impro

289 on spectroscopy revealed V(V) reduction to V(IV) and formation of bidentate corner-sharing surface co

290 genetic variants as instrumental variables (IVs).

291 hylation for oral cedazuridine/decitabine vs IV decitabine, and clinical response.

292 compare adverse event rates associated with IV iron vs red cell transfusion and discuss using first-

293 .01-10.28) of sepsis diagnosis compared with IV piggyback.

294 e linked to Medicare claims and treated with IV tPA at Get With The Guidelines-Stroke hospitals (Febr

295 We identified 293 patients treated with IV tPA who had a prior ischemic stroke within 3 months a

296 Treatment with IV immunoglobulins was associated with improved survival

297 The self-assembly of highly stable zirconium(IV)-based coordination cages with aggregation induced em

298 moisture-stable, visible light-absorbing Zr(IV) photosensitizer, Zr((Mes)PDP(Ph))(2), where [(Mes)PD

299 eport a new light-harvesting mixed-ligand Zr(IV)-based metal-organic framework (MOF),with underlying

300 Consecutive layer-by-layer addition of Zr(IV)-bridged methylenediphosphonic acid enabled positioni